Related references
Note: Only part of the references are listed.Rituximab maintenance therapy of follicular lymphoma in clinical practice
Ulrich Duehrsen et al.
CANCER MEDICINE (2018)
Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20_ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab)
M. Rummel et al.
ANNALS OF ONCOLOGY (2017)
Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study
Pieternella Lugtenburg et al.
HAEMATOLOGICA (2017)
Obinutuzumab for the First-Line Treatment of Follicular Lymphoma
R. Marcus et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study
Pieternella Lugtenburg et al.
HAEMATOLOGICA (2017)
Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial
Andrew Davies et al.
LANCET HAEMATOLOGY (2017)
Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development
Andrew Davies et al.
ADVANCES IN THERAPY (2017)
Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience
Gilles Salles et al.
ADVANCES IN THERAPY (2017)
Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study
Carla Casulo et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study
Ian W. Flinn et al.
BLOOD (2014)
The Use and Effectiveness of Rituximab Maintenance in Patients with Follicular Lymphoma Diagnosed Between 2004 and 2007 in the United States
Loretta J. Nastoupil et al.
CANCER (2014)
Comparison of Subcutaneous Versus Intravenous Administration of Rituximab As Maintenance Treatment for Follicular Lymphoma: Results From a Two-Stage, Phase IB Study
Antonio Salar et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study
Andrew Davies et al.
LANCET ONCOLOGY (2014)
Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience
Daryl Tan et al.
BLOOD (2013)
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
Mathias J. Rummel et al.
LANCET (2013)
Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: A randomised phase III trial
Lisa Lowry et al.
RADIOTHERAPY AND ONCOLOGY (2011)
Rituximab A Review of its Use in Chronic Lymphocytic Leukaemia, Low-Grade or Follicular Lymphoma and Diffuse Large B-Cell Lymphoma
Gillian M. Keating
DRUGS (2010)
Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study
Michael Pfreundschuh et al.
LANCET ONCOLOGY (2008)
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma:: a randomised controlled trial by the MabThera International Trial (MInT) Group
Michael Pfreundschuh et al.
LANCET ONCOLOGY (2006)
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma:: A study by the groupe d'Etude des lymphomes de l'adulte
P Feugier et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Follicular lymphoma international prognostic index
P Solal-Céligny et al.
BLOOD (2004)
An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab
J Boye et al.
ANNALS OF ONCOLOGY (2003)
Rituximab - A review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia
GL Plosker et al.
DRUGS (2003)
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
B Coiffier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Share Paper
